Cargando…
Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
Autores principales: | Choi, Jin-Ho, Lee, Beom Hee, Ko, Jung Min, Sohn, Young Bae, Lee, Jin-Sung, Kim, Gu-Hwan, Heo, Sun Hee, Park, June-Young, Kim, Yoo-Mi, Kim, Ja-Hye, Yoo, Han-Wook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553689/ https://www.ncbi.nlm.nih.gov/pubmed/26339182 http://dx.doi.org/10.3346/jkms.2015.30.9.1373 |
Ejemplares similares
-
A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
por: Choi, Jin-Ho, et al.
Publicado: (2015) -
A multicenter, open-label, phase III study of Abcertin in Gaucher disease
por: Lee, Beom Hee, et al.
Publicado: (2017) -
A multicenter, open-label, phase III study of Abcertin in Gaucher disease: Erratum
Publicado: (2018) -
The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects
por: Kim, Yoo-Mi, et al.
Publicado: (2020) -
Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups
por: Lee, Ju-Young, et al.
Publicado: (2012)